These findings imply that the HLA-E/B2M-CD94/NKG2A axis may partake in tumor immune escape, and corresponding strategies to block B2M/NKG2A may usher in novel prospects for NK cell-based immunotherapy for cancer patients. This evidence concerns the gene KLRC1 and neoplasm.